【优宁维:毛利率下降主要受生物医药类客户需求下降与市场价格竞争加剧影响】金融界3月5日消息,优宁维披露投资者关系活动记录表显示,公司毛利率下降的原因主要是生物医药类客户受资本寒冬影响,融资未有显著好转,导致需求下降。同时,客户对降本增效的需求大幅提升,市场价格竞争加剧,毛利率进一步承压。公司自主品牌整体毛利率约为50%,但目前收入占比较低,随着公司研发投入的持续,公司重组蛋白、IVD抗体、病理IHC抗体、伴随诊断抗体等产品将不断丰富,预计自主品牌收入占比有望提升。

金融界
05 Mar
金融界3月5日消息,优宁维披露投资者关系活动记录表显示,公司毛利率下降的原因主要是生物医药类客户受资本寒冬影响,融资未有显著好转,导致需求下降。同时,客户对降本增效的需求大幅提升,市场价格竞争加剧,毛利率进一步承压。公司自主品牌整体毛利率约为50%,但目前收入占比较低,随着公司研发投入的持续,公司重组蛋白、IVD抗体、病理IHC抗体、伴随诊断抗体等产品将不断丰富,预计自主品牌收入占比有望提升。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10